CYP2D6 polymorphism in patients with eating disorders

Pharmacogenomics Journal

Volumn 12, Issue 2, 2012, Pages 173-175

  Penas Lledo E M ^a   Dorado, P ^a   Aguera Z ^b   Gratacos M ^c   Estivill, X ^c   Fernandez Aranda F ^b,d   Llerena, A ^a,e  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c CENTRE FOR GENOMIC REGULATION CRG   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e HOSPITAL INFANTA CRISTINA   (Spain)

Author keywords

CYP2D6; eating disorders; pharmacogenetics; ultrarapid metabolizers

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; CYP2D6 GENE; EATING DISORDER; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATOR GENE; PRIORITY JOURNAL;

EID: 85027940350     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2010.78     Document Type: Article

References (20)

1. Dorado P, Cáceres M, Pozo-Guisado E, Wong ML, Licinio J, Llerena A. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use. Biotechniques 2005; 39: 571-574.
2. LLerena A, Dorado P, Berecz R, González AP, Peñas- LLedó EM. Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions. Eur J Clin Pharmacol 2004; 59: 869-873.
3. Shapiro JR, Berkman ND, Brownley KA, Sedway JA, Lohr KN, Bulik CM. Bulimia nervosa treatment: a systematic review of randomized controlled trials. Int J Eat Disord 2007; 40: 321-336. (Pubitemid 46651307)
4. LLerena A, Dorado P, Peñas-Lledó EM. Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity. Pharmacogenomics 2009; 10: 17-28.
5. Yu AM, Idle JR, Byrd LG, Krausz KW, Küpfer A, Gonzalez FJ. Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 2003; 13: 173-181. (Pubitemid 36324247)
6. Kirchheiner J, Henckel HB, Franke L, Meineke I, Tzvetkov M, Uebelhack R et al. Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets. Pharmacogenet Genomics 2005; 15: 579-587. (Pubitemid 41044244)
7. Ozdemir V, Bertilsson L, Miura J, Carpenter E, Reist C, Harper P et al. CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisited. Pharmacogenet Genomics 2007; 17: 339-347. (Pubitemid 46608541)
8. Miksys SL, Tyndale RF. Drug-metabolizing cytochrome P450s in the brain. J Psychiatry Neurosci 2002; 27: 406-415. (Pubitemid 36110781)
9. LLerena A, Edman G, Cobaleda J, Benítez J, Schalling D, Bertilsson L. Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr Scand 1993; 87: 23-28.
10. González I, Peñas-Lledó EM, Pérez B, Dorado P, Alvarez M, LLerena A. Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers. Pharmacogenomics 2008; 9: 833-840.
11. Peñas-LLedó EM, Dorado P, Pacheco R, González I, LLerena A. Relation between CYP2D6 genotype, personality, neurocognition and overall psychopathology in healthy volunteers. Pharmacogenomics 2009; 10: 1111-1120.
12. Peñas-Lledó EM, Dorado P, LLerena A. Pharmacogenomics and personality: role of CYP2D6 and implication for psychopathology. In: Schwab M, Kaschka W, Spina E (eds). Pharmacogenomics in Psychiatry. Advances in Biological Psychiatry. Vol. 2. Karger Publishers: Basel, 2010, pp 30-45.
13. Zackrisson AL, Lindblom B, Ahlner J. High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases. Clin Pharmacol Ther 2010; 88: 354-359. (Published online 11 November 2009).
14. Kawanishi C, Lundgren S, Agren H, Bertilsson L. Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur J Clin Pharmacol 2004; 59: 803-807. (Pubitemid 38221657)
15. Josefsson A, Sydsjö G, Berg G, Dahl ML, Wadelius M, Nordin C. CYP2D6 genotypes and depressive symptoms during late pregnancy and postpartum. Nord J Psychiatry 2004; 58: 61-64. (Pubitemid 38351198)
16. Fernandez-Aranda F, Pinheiro AP, Tozzi F, Thornton LM, Fichter MM, Halmi KA et al. Symptom profile of major depressive disorder in females with eating disorders. Aust N Z J Psychiatry 2007; 41: 24-31. (Pubitemid 46705579)
17. Peñas-Lledó E, Fernández-Aranda F, Jiménez-Murcia S, Granero R, Penelo E, Soto A et al. Subtyping eating disordered patients along drive for thinness and depression. Behav Res Ther 2009; 47: 513-519.
18. Ribasés M, Fernández-Aranda F, Gratacò s M, Mercader JM, Casasnovas C, Núñez A et al. Contribution of the serotoninergic system to anxious and depressive traits that may be partially responsible for the phenotypical variability of bulimia nervosa. J Psychiatr Res 2008; 42: 50-57.
19. LLerena A, Dorado P, Peñas-Lledó EM, Cáceres MC, De la Rubia A. Low frequency of CYP2D6 poor metabolizers among schizophrenia patients. Pharmacogenomics J 2007; 7: 408-410.
20. Bacaltchuk J, Hay P. Antidepressants versus placebo for people with bulimia nervosa. Cochrane Database Syst Rev 2003. Issue no 4. Article no. CD003391.